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The Impact of Mentoring as a GMP Capability Building Tool in
The Pharmaceutical Manufacturing Industry in Nigeria
M. Agu1, Z. Ekeocha2, S. Byrn3, K. Clase4 
ABSTRACT
Good Manufacturing Practices (GMP), a component of Pharmaceutical Quality Systems, is aimed primarily at
managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and
efficacy of products. Provision of adequate number of personnel with the necessary qualifications/practical
experience and their continuous training and evaluation of effectiveness of the training is the responsibility of the
manufacturer. (World Health Organization [WHO], 2014; International Organization for Standardization [ISO],
2015). The classroom method of training that has been used for GMP capacity building in the pharmaceutical
manufacturing industry in Nigeria over the years, delivered by experts from stringently regulated markets, have
not yielded commensurate improvement in the Quality Management Systems (QMS) in the industry. It is necessary
and long over-due to explore an alternative training method that has a track record of success in other sectors. A
lot of studies carried out on mentoring as a development tool in several fields such as academia, medicine,
business, research etc., reported positive outcomes. The aim of this study was to explore mentoring as an
alternative GMP training method in the pharmaceutical manufacturing industry in Nigeria. Specifically, the aim of
this study was to evaluate the impact of mentoring as a GMP capability building tool in the pharmaceutical
manufacturing industry in Nigeria, with focus on GMP documentations in XYZ pharmaceutical manufacturing
company located in South-Western region of Nigeria. The methodology comprised gap assessment of GMP
documentation of XYZ company to generate current state data, development of training materials based on the
identified gaps and use of the training materials for the mentoring sessions. The outcome of the study was
outstanding as gap assessment identified the areas of need that enabled development efforts to be targeted at
these areas, unlike generic classroom training. The mentees’ acceptance of the mentoring support was evident
by their request for additional training in some other areas related to the microbiology operations that were not
covered in the gap assessment. This result portrays mentoring as a promising tool for GMP capacity building, but
more structured studies need to be conducted in this area to generate results that can be generalized.
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1. INTRODUCTION
Principles of Pharmaceutical Quality
The Principles of Pharmaceutical Quality System
(PQS) requires the manufacturer to assume
responsibility for the quality of the pharmaceutical
products to ensure that they are fit for their intended
use, comply with the requirements of the marketing
authorization and do not place patients at risk due to
inadequate safety, quality or efficacy. The attainment
of this quality objective is the responsibility of senior
management and requires the participation and
commitment of staff in different departments and at all
levels within the company, the company’s suppliers
and the distributors. To achieve this quality objective
reliably there must be a comprehensively designed
and correctly implemented pharmaceutical quality
system (PQS) incorporating GMP and QRM. (WHO,
2014, p. 85-86).
ICH Q10 Guideline - Pharmaceutical Quality System
is described as one comprehensive model for an
effective pharmaceutical quality system that is based
on International Organization for Standardization
(ISO) quality concepts including applicable Good
Manufacturing Practice (GMP) regulations and
complements ICH Q8 “Pharmaceutical Development”
and ICH Q9 “Quality Risk Management (QRM)”.
“ICHQ10 is a model for a pharmaceutical quality
system that can be implemented throughout the
different stages of a product lifecycle. Much of the
content of ICH Q10 applicable to manufacturing sites
is currently specified by regional GMP requirements”
(ICH Q10 Guideline, 2008).
Good Manufacturing Practices (GMP) is that part of
quality management which ensures that products are
consistently produced and controlled according to the
quality standards appropriate to their intended use
and as required by the marketing authorization,
clinical trial authorization or product specification.
GMP is concerned with both production and QC. GMP
is aimed primarily at managing and minimizing the
risks inherent in pharmaceutical manufacture to
ensure the quality, safety and efficacy of products.
(WHO, 2014, p.90).
The manufacturer is required to have an adequate
number of personnel with the necessary qualifications
and practical experience. This is because the
establishment and maintenance of a satisfactory
system of Quality Assurance (QA) in addition to the
correct manufacture and control of pharmaceutical
products and active ingredients rely upon people.
(WHO, 2014, p. 99). It is the manufacturer’s
responsibility to provide training for “all personnel
whose duties take them into manufacturing areas or
into control laboratories (including the technical,
maintenance and cleaning personnel), and for other
personnel as required”. They should be given
continuous training and practical effectiveness of the
trainings should be periodically assessed. (WHO,
2014. P. 103).
The quality, safety and efficacy of pharmaceutical
products manufactured in Nigeria are regulated by
National Agency for Food and Drug Administration
and Control (NAFDAC) through her GMP guideline -
NAFDAC Good manufacturing practice guidelines for
pharmaceutical products, 2016 amongst other
guidelines.Though, the national guideline is aligned
with the WHO Good Manufacturing Practices for
Pharmaceutical Products: Main Principles, the WHO
GMP guideline is universally accepted as the
minimum standard of GMP. Hence, the WHO
guideline will be used as a standard upon which the
GMP documentation of XYZ pharmaceutical
manufacturing company will be assessed. It is the
ultimate goal of this work that local pharmaceutical
manufacturers in Nigeria be able to place products in
the stringent regulated markets in the near future. To
facilitate this goal, the PICS GMP Guide (2018):PE
009-14 (Part I) - Guide to Good Manufacturing
Practice for Medicinal Products, was also used as a
second standard since this is the common standard
used by regulators in the stringently regulated
markets for inspections.
History of local pharmaceutical manufacture in
Nigeria
Mackintosh, Banda, Wamae, & Tibandebage, 2016
(as cited in Lartey, Graham, Lukulay, & Ndomondo-
Sigonda, 2018) stated that the first pharmaceutical
manufacturing facilities in Nigeria were set up in 1945
by Multinational companies. The enactment of the
Indigenization Policy in 1978 by the Nigerian
Government forced most of the multinational
companies to sell 60% of their shares to Nigerian
investors. It is important to note that investors go into
business to have return on their investment and may
not understand the technicalities of running such
businesses. The Indigenization Policy era was
followed by the Import License regime, a period
characterized by a very unfriendly economic
environment prohibiting ease of doing business. The
result was gradual divestment of multinational
companies from local pharmaceutical manufacturing
in the country. The outcome was emergence of 100%
locally owned pharmaceutical manufacturing facilities
in Nigeria (Ogbonna, Ilika, & Nwabueze, 2015), with
many new entrants. Thus, Nigeria became the leading
pharmaceutical manufacturing country in Sub-
Saharan Africa, (Wambebe, & Ochekpe, 2011 as
cited in Lartey, Graham, Lukulay, & Ndomondo-
Sigonda, 2018), with about 200 local pharmaceutical
manufacturing facilities, as reported in the baseline
 
 
      
       
     
        
         
     
 
      
         
       
         
       
      
        
     
        
       
          
     
        
           
        
      
          
      
       
        
        
 
       
           
         
        
         
        
       
       
        
       
           
        
        
      
     
        
       
         
         
      
       
         
         
       
     
      
       
       
     
      
       
      
      
      
       
       
   
      
  
        
    
      
      
        
      
     
          
          
       
       
        
        
       
        
       
          
       
        
        
        
         
       
       
        
        
        
       
        
      
 
      
           
      
         
        
        
      
      
         
       
3
assessment of the Nigerian pharmaceutical sector,
published by World Health Organization (2002). The
numerical growth of pharmaceutical manufacturing
facilities in Nigeria did not have commensurate growth
in the Quality Management Systems of the industry.
Development of Pharmaceutical Manufacturing in
Africa
The pharmaceutical manufacturing industry in Nigeria
is not alone in the dilemma of slow technical
development. The issue cuts across the Sub-Sahara
African (SSA) region and even Africa as a continent.
Despite the age of the local pharmaceutical
manufacturing industry in Sub-Saharan Africa, the
rate of development is extremely slow. “It is
instructional to note that pharmaceutical
manufacturing started in India in 1930” (Indian Mirror
as cited in Lartey, Graham, Lukulay, & Ndomondo-
Sigonda, 2018), the same year as in SSA. In the
1970s, the Indian pharmaceutical manufacturing
industry started its exponential growth (Shah, 2012 as
cited in Lartey et al 2018), and is far more advanced
than the industry in Africa with Indian manufacturers
exporting medicines to stringent regulated markets,
such as the USA and Europe. However, the story is
different for the African local pharmaceutical
manufacturing industry that is still struggling and
unable to be self-sufficient in producing quality, safe
and efficacious medicines for the patients in the
continent.
The World Health Organization (2013) estimated that
over 70%, or 37 million persons, living with HIV are in
SSA and only 35% of them have access to
antiretrovirals (Global HIV & AIDS statistics — 2019
fact sheet | UNAIDS), which are mostly supplied by
donor Agencies like Global Fund who procure World
Health Organization pre-qualified generics. Out of the
172 formulations (WHO, 2017) pre-qualified by WHO
(WHO-PQ) for the treatment of HIV and associated
opportunistic infections, only six are manufactured in
Africa while 119 are from India (Lartey et al 2018). The
lack of exponential growth coupled with absence of
backward integration to cover the entire value chain
(which involves new drug discovery, development,
active pharmaceutical ingredient manufacturing and
manufacture of finished dosage forms), has made it
alarmingly apparent that Africa is heavily dependent
on others for its medicine supply and public health.
This looming security threat led to recognition of the
pharmaceutical manufacturing sector as vital to
sustainable development and was instrumental to the
resolution of the African Union (AU) Heads of State
and Government to develop the sector (Lartey et al
2018). The outcome was the development of
pharmaceutical manufacturing plan for Africa:
business plan. (PMPA-BP). The stakeholders drafted
the terms of reference, enabling the partnership
between (Africa Union Congress (AUC) and the
United Nations Industrial Development Organization
(UNIDO) to oversee development of the PMPA-
Business Plan (Ngozwana et al 2012). Several
studies sponsored by Deutsche Gesselschaft fur
Technische Zussamennar and UNIDO, conducted in
some key manufacturing countries including Ghana,
Kenya, Nigeria and Uganda, led to comprehensive
delineation of common challenges facing the industry.
These included:
1. Poor compliance with Good Manufacturing
Practices (GMP);
2. Lack of effective regulatory capacity of National
Medicines Regulatory Authorities (NMRAs);
3. Unfavorable business and market dynamics;
4. Inadequate application of business principles;
5. Lack of government support and political will;
6. Lack of access to capital.
The Nigerian pharmaceutical manufacturing industry
is weighed down by all these challenges, just like the
other countries in Africa that were part of the studies.
Despite these challenges, a few companies have
worked hard to achieve international GMP standards
with the intention to have products prequalified by
WHO.This was made possible through the support of
the Nigerian Health Authority, National Agency for
Food and Drug Control (NAFDAC) and the World
Health Organization (WHO), (Ngozwana et al 2012).
It is also documented in the PMPA-BP that there is
evidence that production to international standards is
possible across our continent and that we have
entrepreneurs with the appetite for risk, energy, and
commitment to achieve these goals. However, as well
as these (and other) leading players, we know that
there are many other companies licensed to
manufacture products whose quality systems fall in
some cases way below what should be acceptable.
Whilst there has been no systematic study, experts
who have visited plants, and comments by regulators
with access to confidential GMP inspection reports,
provide categorical evidence that this is the case.
(Ngozwana, West, Olajide, & Byaruhanga, 2012).
With Nigeria leading in pharmaceutical manufacturing
in SSA with about 200 players, it implies that a good
number of pharmaceutical manufacturers in Nigeria
are likely to be among the “other companies licensed
to manufacture products whose quality systems fall in
some cases way below what should be acceptable”
(Ngozwana, West, Olajide, & Byaruhanga, 2012).
Poor compliance with Good Manufacturing Practices
(GMP) was identified as number one challenge in the
PMPA-BP. It is common knowledge that the
 
 
      
        
       
       
      
        
        
      
       
        
    
     
    
     
       
         
     
     
       
      
       
        
       
      
      
         
        
        
    
      
         
   
    
         
         
          
       
       
       
     
      
      
      
          
        
         
        
        
           
     
      
          
         
       
        
   
   
         
 
       
          
  
         
       
   
         
       
      
    
       
        
    
 
 
          
       
       
   
   
          
          
      
          
          
        
       
       
        
        
  
        
       
        
       
            
         
         
         
      
        
      
     
     
      
      
        
        
     
4
pharmaceutical manufacturing industry in Nigeria has
benefitted from many GMP training by experts from
the stringent regulated markets. However, most of
these trainings were delivered using the conventional
classroom approach. This approach has been
criticized “for being finite, passive, not social, and
disconnected from real practice, resulting in less than
optimal learning” (Martin et al2014). The
ineffectiveness of classroom / presentation method of
training was succinctly captured by Murray, (2002) in
the following statement.
There is growing disenchantment with
conventional educational and training
programs offered within organizations. Such
formal training for specific skills is essential,
and we are not suggesting that it be replaced
by mentoring. However, when training
courses use traditional academic formats
such as lecture and presentation, the busy
manager gets frustrated and bored. Many
times there is no follow-up to determine
whether skills are applied back on the job.
The bottom line is that attitudinal and
behavioral changes are extremely difficult to
accomplish, especially for the individual left
on his or her own. In formal training the
content may be conveyed but not the context
for application of that knowledge to the work
environment. The perceptions and
experiences of the mentor provide that
context, as well as a model of behavior worthy
of emulation.
The ineffectiveness of classroom/presentation
method of training (Murray, 2002) as well as the
observation by Bjursell & Sädbom (2018) that it might
be difficult, or even impossible, to apply what one has
learned (from traditional training approach) when one
returns to one’s workplace, explains the slow
progress in the development of the Quality
Management Systems in the pharmaceutical
manufacturing industry in Nigeria. The slow
development of technical capabilities in the
pharmaceutical manufacturing industry in Nigeria is
the problem that this study is trying to solve by
exploring the use of mentoring as GMP capability
building tool. Gap assessment is a tool used in
pharmaceutical industry to identify gaps to be worked
on for continuous improvement of the quality systems.
This tool was used to identify the areas of need in
GMP documentation in XYZ pharmaceutical
manufacturing company. The mentoring program was
targeted at the identified gaps. In view of the problem
that this study aimed to solve and adopting gap
assessment for needs identification, the next section
described the research questions that this study was
to answer.
Research Question
Below are the questions that this study aimed to
answer:
• Research question 1: Can Gap Assessment
serve as a tool for assessing training needs in a
mentoring program?
• Research question 2: Can mentoring serve as a
GMP training method targeted at the mentees’
and organizational needs?
• Research question 3: Will mentoring serve as a
method for presenting GMP training to aid
knowledge transfer, ease of understanding and
application of knowledge acquired?
• Research question 4: Can mentoring gain
acceptance as a GMP training method, in the
pharmaceutical manufacturing industry in
Nigeria?
Prior to initiating the study, a review of literature on
mentoring was conducted to understand the current
knowledge on mentoring, especially mentoring in the
workplace.
The search strategy
The purpose of this study was to explore the impact
of mentoring as a GMP capability building tool in the
pharmaceutical manufacturing industry in Nigeria.
The use of mentoring as a GMP training method is
new to the industry. Therefore, it was not likely that
studies on this topic existed in the literature.
Therefore, the literature search was generic on
mentoring as a capability building tool. The
knowledge obtained from the studies in other fields
assisted in the adaptation of mentoring for GMP
training.
A preliminary search for the keywords mentoring and
“capability building” and their synonyms coaching and
“capacity building” in Google Scholar, Web of Science
and EBSCOhost databases was done. The results
were too large and review of the titles in the first few
pages of the search results from the three databases
showed that most of the articles did not have
relevance to the title of this study. The following
additional keywords (impact of mentoring program,
impact of mentoring on capability building, impact of
mentoring programs in GMP capability building,
mentoring program effectiveness, effectiveness of
mentoring program, Effectiveness of mentoring
program on capability building, Effectiveness of
mentoring programs in GMP capacity development)
were used in the subsequent searches which were
refined using the Boolean operators and limiters. The
inclusion criteria were peer-reviewed articles
5 
published between1999 to 2019 and related to 
workplace mentoring program. The date range of 
publications was restricted to 1999 and 2019 (articles 
published in the past twenty years), so that review 
could be built on the recent literature, considering 
changes in method of information retrieval and 
synthesis due to technological advancement (Xiao & 
Watson, 2019). 
After review of the titles of the articles in the search 
results of the 3 databases, 228 peer-reviewed journal 
articles were selected. Most of the articles were on 
studies in academic / youth mentoring and some on 
mentoring in medical education and practice. The 
literature search did not turn in any study on use of 
mentoring as GMP capability building tool in the 
pharmaceutical manufacturing industry. Few peer-
reviewed articles with focus on effectiveness of 
mentoring in other fields like education, medicine and 
business were selected for review. For instance, 
study by Núñez, Rosário, Vallejo & González-Pienda, 
(2013) in academic setting showed positive results. 
The study by Pillai, Chibale, Constable, Keller, 
Gutierrez, Mirza, ... & Ramsay, (2018) is interesting 
as it mimicked the Biotechnology Innovation and 
Regulatory Sciences (BIRS) program model and 
demonstrates an example of how multi-sectoral 
partners can contribute to scientific and professional 
development of researchers in low- and middle-
income countries (LMICs). It supports the idea that 
capacity-building efforts should be tailored to the 
specific needs of beneficiaries to be maximally 
effective. 
BIRS capacity-building model is a program by Purdue 
University USA that is enabling the manufacture of 
quality medicines in Africa for Africans by equipping 
leaders in pharmaceutical industry in Africa with the 
requisite knowledge and skills through higher 
education aligned with building industrial capacity 
(Clase Ekeigwe, Mann, Mukungu, & Mwangomo, 
2019). 
The review of mentoring literature in the medical field 
by Buddeberg-Fischer and Herta, (2006) revealed 
that majority of the programs lacked concrete 
structure as well as short- and long-term evaluation. 
Though these studies were not specifically in an 
organizational work setting similar to pharmaceutical 
manufacturing industry, there is learning that can be 
of importance in planning a mentoring program in a 
pharmaceutical manufacturing organization. 
Additional relevant peer-reviewed journal articles 
were identified by forward and backward citation 
search. The selection of articles through this method 
was made taking into consideration the date of 
publication (1999 –2019) set as inclusion criterion. A 
few of the articles selected through this “snowballing” 
approach were published before 1999 but were 
included in the list of articles for review because of 
their relevance to this study. The abstracts of the 
selected articles were reviewed, in addition to the 
discussion, before final decision on inclusion was 
made. After this process, the number of peer-
reviewed journal articles that are original research 
and review articles selected due to their relevance to 
this study reduced to 16 with a book on mentoring 
included. Other articles included were mainly 
regulatory references relevant to pharmaceutical 
manufacturing compliance. The citation of all the 
selected articles were exported to an EndNote Basics 
account and retrieved from there for review and 
synthesis. 
Next, a literature map was prepared with select 
articles, using the top-down approach concluding at 
the bottom with the proposed study (Creswell & 
Creswell, 2017) as shown in Figure 1 below. 
Effectiveness of 
mentoring program 
Egan & Song (2008) 
Informal mentoring 
Formal mentoring in 
medicine and related fields 
Pillai, Chibale, Constable, 
Keller, Gutierrez, Mirza, F... 
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Figure 1: Literature map
The starting point of the literature review was to find
out what the construct called “Mentoring” means.
What is Mentoring?
Historically, mentoring is an ancient archetype
originating in Greek mythology. A figure in Homer’s
Odyssey, Mentor was a wise and faithful advisor
 
 
      
        
         
            
           
        
        
         
        
        
      
        
        
      
       
       
       
          
 
    
          
        
          
        
       
       
         
         
        
        
         
        
     
        
          
          
       
         
       
         
        
     
       
     
      
       
       
      
      
       
     
     
 
 
    
      
       
       
      
     
      
      
      
       
      
       
       
      
       
      
       
        
          
  
       
      
        
        
       
      
      
          
       
 
     
         
    
       
      
          
      
       
  
         
       
     
  
         
       
        
     
       
      
       
      
  
6
entrusted to protect Odysseus’s son, Telemachus,
while Odysseus sailed against Troy. While the roots
of mentoring can be traced to mythology, mentoring is
no myth; it is a very real relationship that has been an
integral part of social life and the world of work for
thousands of years (Ragins & Kram, 2007).
There are many definitions of mentoring in literature,
but Ragins & Kram, (2007) integrated the views of
Kram, (1985); Levinson, (1978); Noe et al., (2002);
Ragins, (1999) and Wanberg et al., (2003) and
defined traditional mentoring as a relationship
between an older, more experienced mentor and a
younger, less experienced protégé for the purpose of
helping and developing the protégé’s career.
Traditional mentoring is an informal relationship that
emerges largely through mutual initiation and ongoing
connections between protégé and mentor (Ragins &
Cotton, 1991 as cited in Egan & Song, 2008).
Who is a Mentor?
It is also important to understand who a mentor is.
According to Ehrich, Hansford & Tennent, (2004), the
original meaning of the word mentor refers to a “father
figure” who sponsors, guides and develops a younger
person. Throughout history, mentors have played a
significant role in teaching, inducting and developing
the skills and talents of others (Ehrich, Hansford &
Tennent, 2004). Carol Sankar, a Forbes Council
member and Founder of “The Confidence factor for
Women in Leadership” summed up the importance of
having a mentor in her post on Forbes Coaches
Council titled “Behind Every Great Leader are Great
Mentors and Advisors.” Sankar (2017).
According to Ragins and Kram (2007), the mentor
may or may not be employed in the same organization
as the protégé or be in the protégé’s chain of
command or profession. Mentors are viewed as
providing two types of function to their protégés and
these are career and psychological functions (Kram,
1985 as cited in Ragins & Kram, 2007). Career
functions involve a range of behaviors which include
coaching protégés, sponsoring their advancement,
increasing their positive exposure and visibility, and
offering them protection and challenging
assignments. Psychosocial functions build on trust,
intimacy, and interpersonal bonds in the relationship
and include behaviors that enhance the protégé’s
professional and personal growth, identity, self-worth
and self-efficacy. They include mentoring behaviors
such as offering acceptance and confirmation and
providing counseling, friendship, and role-modeling
(Ragins & Kram, 2007).
Types of Mentoring relationships
Historically, mentoring started as an informal
relationship referred to as traditional mentoring in
mentoring literature. But with the introduction of
mentoring into formal developmental processes in
educational and business organizations, formal
mentoring came into existence. Informal mentoring
relationships emerge largely through mutual initiation
and ongoing connections between protégé and
mentor and occur over time without external
intervention or planning. However, formal mentoring
relationships are most often initiated by organizational
representatives and involve a process for assigning
employees or managers to mentors: mentor-protégé
pairing. The internal organizational facilitators may set
expectations for involvement such as: mandatory
participation, induction or ongoing training, number of
meeting times, topics for discussion and goal setting
(Ragins & Cotton, 1991 as cited in Egan & Song,
2008).
In literature, different mentoring models exist: the
classic one-to-one mentoring between mentor and
mentee; group mentoring, a (small) group of mentees
supervised by a mentor; individual or group mentoring
with a number of mentors (the multiple-mentor
experience model); and mentoring among co-equals
(peer mentoring) (Buddeberg-Fischer & Herta, 2006).
These types of mentoring fall into either of the two
theoretical forms of mentoring: traditional or relational
mentoring.
Phases in the Mentoring Process
Kram (1983) described the following four phases in a
mentoring relationship: initiation, cultivation,
separation and redefinition. Her brief description of
each phase is as stated below:
• Initiation: A period of six months to a year
during which time the relationship gets
started and begins to have importance for
both managers.
• Cultivation: A period of two to five years
during which the range of career and
psychological functions provided expands to
a maximum.
• Separation: A period of six months to two
years after a significant change in the
structural role relationship and / or in the
emotional experience of the relationship.
• Redefinition: An indefinite period after the
separation phase during which time the
relationship is ended or takes on significantly




        
         
       
       
       
         
        
     
 
      
 
       
       
          
        
      
         
          
  
       
      
      
        
        
       
        
       
         
        
       
        
       
       
      
       
         
        
       
       
        
        
       
      
        
       
      
       
     
         
         
          
       
          
         
        
       
        
        
        
        
        
        
       
       
        
          
        
        
         
        
        
        
      
      
        
         
           
      
  
         
         
        
        
       
      
      
      
      
      
       
      
       
        
         
      
       
        
       
         
       
      
     
        
     
      
        
     
     
       
       
       
7
Kram’s phases in mentoring process was based on
the context of mentoring in the workplace where a
senior manager mentors a young manager. As
mentoring models have evolved, strict adherence to
the proposed activities and, especially, the timelines
for each phase may not be sacrosanct. However, this
phase approach is a good guide for modeling one-to-
one mentoring relationship (Kram, 1983).
Strengths and Weaknesses of Mentoring
There are strengths and weaknesses in humans,
processes and everything that is in existence.
Mentoring is not an exception. It has its strengths and
weaknesses too; and the magnitude will depend on
diligence in planning, execution, monitoring and
evaluation on both the mentors and the mentees, who
should serve in their roles in order to achieve the
desired goals.
A structured analysis of over 300 research-based
papers on mentoring across three disciplines
(educational, medical and business) was conducted
by Ehrich, Hansford & Tennent, (2004) in their
“attempt to make more valid inferences about the
nature and outcomes of mentoring”. Specifically, their
analysis was to determine the positive and more
problematic outcomes of mentoring for the mentor,
the mentee and the organization. The result of the
analysis revealed that in the business studies, the
most frequently cited positive response (50.3%) for
the mentees was “career satisfaction / motivation /
plans / promotion”. While “coaching / feedback/
strategies” was rated in second place (30.5%),
“challenging assignments / improved skills /
performance” was the third (23.2%) and “counselling
/ listening / encouragement” was the fourth. For the
mentors, “networking / collegiality” came out as the
most frequently cited positive response (7.9%). While
“career satisfaction / motivation / promotion” (7.3%);
“improved skills / job performance” (6.6%) and “pride
/ personal satisfaction” (6.6%) were the other three
most frequently cited positive outcomes for mentors.
Career development and skill enhancement emerged
prominently in the analysis, in alignment with the
outcomes for mentors and mentees in business
literature (Ehrich, Hansford & Tennent, 2004).
The education, business and medical reviews had
similar problematic outcomes experienced by
mentors and mentees. “Lack of time” frequently cited
in the reviews, was the most commonly cited problem
by mentors in the business studies (6%). It was also
identified in the medical studies. “Negative mentee
attitude / lack of trust / cooperation” (5.3%) and “little
training or little knowledge about the goals of the
program” (4.6%), were the second and third most
frequently cited problematic outcomes for mentors in
the business review. Mentors and mentees in the
medical studies viewed lack of mentor training as
detrimental to the program. While “jealousy / negative
attitudes of others” was the fourth most frequently
cited problematic outcome for mentors (except in the
medical studies). In the medical studies, “the extra
burden or responsibility that mentoring created for
mentors” emerged as a problematic workload issue.
For the mentees in the business studies, “issues
relating to race and gender (7.9% of the studies)” and
“cloning or conforming or over-protection (7.3% of the
studies)” were the two most frequently cited problems.
The race and gender issues arose as a consequence
of matching female mentees with male mentors and
black mentees with white mentors. The third most
frequently cited negative outcome for mentees in the
business studies was “ineffective and untrained
mentors” (6.6%). While “problematic attitude of
others” (6%) came fourth. In the medical studies,
perception of the mentees that seeking help was a
signal of weakness or inability to cope came out as an
important problematic outcome. (Ehrich, Hansford &
Tennent, 2004).
Almost twice as many business studies (30.5%) cited
one or more positive outcome for the organization, in
contrast to the education studies. The most frequently
cited benefit reported in 13.9% of studies was
improved productivity / contribution / profit by
employees. Other positive outcomes from the
business studies included retention of talented
employees (11.9%), promotes loyalty (6.6%) and
improves workplace / communications / relations
(4%). (Ehrich, Hansford & Tennent, 2004).
Both the education and business literature featured
fewer studies reporting problematic outcomes of
mentoring for the organization. Two of these
problematic outcomes cited in more than a single
study were high staff turnover (which was seen to
hinder the development of long-term relationships
between mentors and mentees) and gender or
cultural bias in the organization (which resulted in
good staff being overlooked in the mentoring
process). In seven out of the eight medical studies
reviewed, organizational or attitudinal barriers was the
most frequently cited problematic outcome of
mentoring. The problematic organizational problems
in the medical studies included ambivalence to the
project by management, minimal management
support, resource issues, schedule planning issues
and belief that mentoring should not be formalized.
(Ehrich, Hansford & Tennent, 2004).
Results from a one-year longitudinal quasi-
experiment that examined the effectiveness of a
formal mentoring program at a Fortune 100
corporation showed that subjects with formal mentors
 
 
       
          
      
      
         
     
         
        
         
       
          
      
       
            
      
       
  
       
       
          
         
         
         
         
        
    
          
        
       
     
          
         
      
           
         
       
        




        
        
       
        
    
     




   
         
        
       
       
           
       
        
        
     
      
   
         
      
      
 
         
    
     
          
      
    
       
       
        
           
         
  
         
        
       
          
        
        
         
       
        
       
      
 
        
        
          
      
       
       
         
  




reported significantly higher levels of job satisfaction,
while a small to medium effect for “participation” in the
mentor program was observed for organizational
commitment (Seibert, 1999). This corroborates the
results for mentors and mentees in the review by
Ehrich, Hansford & Tennent, (2004).
The results of the survey questions sent by Emelo
(2011) to 211 participants, across 24 different group
mentoring events with a total of 73 people (35%
response rate) showed two key findings:
1. 93% of responders reported that the topics of the
mentoring programs they participated in were
relevant to their roles in their organizations.
2. A total of 96% reported that they could apply the
information gained from the group mentoring
experience directly to their roles in their
organizations.
Results from a provincial government ministry group
mentoring program showed that 87% of mentees
rated their learning as effective. Relevance of the
learning and the use of current issues, events and
personal stories by the senior leader / mentors were
some of the benefits reported by the mentees. (Harris,
Cheng & Gorley, 2015). These reports are all aligned
on the effectiveness of group mentoring from the
perspective of the mentees.
It is important to note that the model of mentoring
planned for this research was formal group mentoring,
where the mentors were from outside the
organization. Therefore, the problematic experiences
in the studies in the above review that arose because
the mentors and mentees were working in the same
organization were automatically eliminated in this
study. But the concern for lack of time observed in the
above review was encountered in this study at the
beginning during the presentation of the project
charter, when the department heads objected to the




As the study design was documentation review, there
was no need for ethics committee approval. However,
the researcher and the Subject Matter Experts
(SMEs) signed and presented to the management of
XYZ pharmaceutical manufacturing company,
confidentiality agreement pledging to maintain
confidentiality of the company information. (See
Appendix: I).
Design and Implementation
This study is a basic type of Qualitative research
(Creswell & Creswell, 2017). Selection of the
organization where the study was performed was
done by convenience sampling method.The aim of
the study was to explore the use of mentoring as a
GMP capability building tool in the pharmaceutical
manufacturing industry in Nigeria. The focus was on
GMP documentation review at a company called XYZ
pharmaceutical manufacturing company (for reason
of confidentiality), located in the South-Western
region of Nigeria.
The first step was preparation of a Gap Assessment
Template (with Microsoft Excel) on GMP
documentation by the researcher using two
references:
• WHO TRS 968, (2014). Annex 2 -WHO good
manufacturing practices for pharmaceutical
products: main principles, and
• PICS GMP Guide (2018): PE 009-14 (Part I) -
Guide to Good Manufacturing Practice for
Medicinal Products guidelines.
Corrections of errors in the prepared Gap
Assessment Template (GAT) was done by the
researcher and cross-checked by one of the SMEs
before the instrument was put to use in the review of
the GMP documentations of the XYZ company by the
two SMEs.
Each of the SMEs cross-checked the records of the
review done by the other expert and any
disagreement discussed and resolved with the author
and the researcher. This was to generate data on the
current state of the GMP documentation in the
company. This method for conducting needs
analysis was a tool for continual improvement in GMP
environment and is aligned with Tannenbaum and
Yukl (1992) who stated that “the importance of
conducting a thorough needs analysis is well
accepted in the training literature.”
The initial plan to prepare a specimen Corrective
Action, Preventive Action (CAPA) plan based on the
identified gaps to be used as training materials for the
mentoring program was dropped. Instead, sample
Standard Operating Procedure on Writing of Standard
Operating Procedures (SOP of SOPs) was prepared




     
          
       
     
 
           
           
          
    
  
         
         
        
         
     
       
        
        
        
      
           
          
        
        
  
        
         
         
   
  
          
         
         
       
        
        
          
         
        
       
       
          
       
        
     
          
      
        
      
          
         
         
       
      
      
      
      
         













          
       
 
   
         
       
     
      
       
          
          
       
        
   
        
        
         
        
        
       
        
   
      
 
      
     
 
 




3. RESULTS AND DISCUSSION
A total of 42 gaps were identified from the GMP
documentation review. They were documented in the
GAT. See Appendix: II.
Coding
Open and axial coding of the data was done. Before
reporting the results of the open and axial coding, it is
importatnt to give a brief expanation of the meaning of
open and axial coding.
Open Coding
Open coding, commonly used as first step in the
analysis of qualitative research, is often used as the
initial coding pass in Grounded Theory. With open
coding, data is broken down into discrete parts and
“codes” created to label them.
As the name implies, open-coding opens the
researcher up to new theoretical possibilities, as he
starts collecting the qualitative data. Breaking up the
data and labeling them with codes enables the
researcher to continuously compare and contrast
similar events in the data. This is done by collating all
pieces of data (such as quotes) that were labeled with
a particular code. This process forces the researcher
out of preconceived notions and biases about his
research.
Open coding in qualitative research most times is
followed by one or more coding methods, such as
Axial Coding. (Corbin & Strauss, 1990 as cited in
Delve blog, n.d.).
Axial Coding
Axial coding is the second step in coding that follows
open coding in grounded theory. In contrast to open
coding where the data is broken into discrete parts,
with axial coding connections are drawn between
codes. With axial coding in qualitative research, the
researcher reads over the codes and the underlying
data to find how the codes can be grouped into
categories. “A category could be created based on an
existing code, or a new category developed that
encompasses a number of different codes. After
conducting axial coding, a number of categories
emerge out of a set of supporting codes. These
categories are the “axes” around which their
supporting codes revolve. (Corbin & Strauss, 1990 as
cited in Delve blog, n.d.).
Out of the 42 gaps identified, 40 were due to non-
compliance to Good Documentation Practices, while
two were due to Data Integrity issues. Therefore,
“Good Documentation Practices” and “Data Integrity”
where chosen as codes for coding of the 42 gaps
identified using manual open coding. Appendix III
shows manual open coding of GMP gaps identified in
XYZ Company Documentation Systems.
The codes “Good Documentation Practices” and
“Data Integrity” are components of “Document
Management Systems”. Therefore, using axial coding
method, “Document Management Systems” is the
category that connects the two codes as shown in
Figure 2 below.
Figure 2: Axial Coding (of codes from open coding) of
GMP gaps identified in XYZ Company Documentation
Systems.
The mentoring process
A trend discovered in all the SOPs (which formed
majority of the documents reviewed), was poor
document design, which originated from non-
compliant Standard Operating Procedure on Writing
of Standard Operating Procedures (SOP of SOPs).
Since the root cause of the gaps was poor document
design , the initial plan to prepare a Corrective Action,
Preventive Action (CAPA) plan (after the GMP
documentation review) to be used for mentoring was
dropped.
Instead, one of the Subject Matter Experts (SMEs)
prepared sample SOP of SOPs (Appendix IV). The
completed GAT and the sample SOP of SOPs were
used as training materials for the mentoring sessions.
Also, the mentees requested training on the following
areas that were found challenging:
• How to establish growth promotion test for
pharmaceutical culture media;
• Environmental and plant hygiene monitoring;
• Trend analysis of environmental monitoring,
water and microbial limit results.
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One of the SMEs prepared sample SOPs on these
topics and these were used as training materials
together with power point slides on growth promotion
test during the mentoring session. These are found in:
Appendix V: Sample SOPs on How to establish
growth promotion test for
pharmaceutical culture media;
Appendix VI: Sample SOP on Trend analysis of
environmental monitoring, water and
microbial limit results;
Appendix VII: Environmental and plant hygiene
monitoring;
Appendix VIII: Power point slides on Growth
promotion test.
The mentoring process was interactive and the
training targeted at the areas of need of the
organization/mentees and performed by mentors who
were experts and experienced in pharmaceutical
GMP. The effectiveness of the mentoring sessions
was evident by the request for additional support in
other areas outside the gaps identified during the
documentation review.
The emergence of 2 sub-themes (Data Integrity and
Good Documentation Practices), both of which were
integrated to form the main theme, “Document
Management System”, is a pointer to the knowledge
gap that exists in the company. Also, the finding that
majority of the gaps fell under non-compliance to
Good Documentation Practices is an indication of a
general knowledge gap on the regulatory
requirements, despite previous classroom trainings
attended on this subject. It is therefore important to
provide a summary of these sub-themes (Data
Integrity and Good Documentation Practices) and
main theme Document Management System.
Data Integrity
According to US FDA draft Guidance - Data Integrity
and Compliance with cGMP Guidance for Industry,
“data integrity refers to the completeness,
consistency, and accuracy of data. Complete,
consistent, and accurate data should be attributable,
legible, contemporaneously recorded, original or a
true copy, and accurate (ALCOA)” (US FDA, 2016).
This definition is also aligned with WHO draft Working
Document QAS/19.819, 2019. (WHO,2019)).
However, PIC/S Guidance, PI 041-1(Draft 3), 2018
has additional attributes to form ALCOA +. These
additional attributes are complete, consistent,
enduring and available.
Good Documentation Practices
“Good documentation practices are those measures
that collectively and individually ensure that
documentation, whether paper or electronic, is
secure, attributable, legible, traceable, permanent,
contemporaneously recorded, original and accurate.”
(WHO, 2016)
Document Management System
WHO TRS 996, Annex 5, (2016) describes the
principles of Good Document and Records Practices
as a systematic approach that should be implemented
to provide a high level of assurance that throughout
the product life cycle, all GxP records and data are
complete and reliable. The US FDA draft Guidance on
Data Integrity and Compliance with cGMP Guidance
for Industry describes it as Data Governance System.
According to this guidance, data governance is the
sum total of arrangements which provide assurance
of data quality. These arrangements ensure that data,
irrespective of the process, format or technology in
which it is generated, recorded, processed, retained,
retrieved and used will ensure attributable, legible,
contemporaneous, original, accurate, complete,
consistent, enduring, and available record throughout
the data lifecycle. The data lifecycle refers to how data
is generated, processed, reported, checked, used for
decision-making, stored and finally discarded at the
end of the retention period.
In other words, a pharmaceutical manufacturing
company should have a system of managing the
records and data for the products they are producing
in order to give assurance of the completeness and
reliability of the records and data throughout the
product’s life cycle. Failure to do this implies that the
records and data attesting to the quality, safety and
efficacy of the products are questionable and the
patients taking the products are exposed to risk.
Therefore, it is very critical that all personnel involved
in the processes of generating and handling data and
records in a GMP environment be given training using
a method that will aid their understanding and
application of knowledge gained.
The gap assessment of the GMP documentations of
XYZ pharmaceutical manufacturing company using
the GAT (generated from the requirements of the
regulatory guidelines), adequately identified the
needs of the mentees and the organization. By
targeting the mentoring efforts on the areas of need of
the mentees and the organization, this study has
positively answered the Research questions 1 and
2 below:
• Research question 1: Can Gap Assessment
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• Research questions 2: Can mentoring serve as
a GMP training method targeted at the mentees’
and organizational needs?
This outcome corroborates the finding by Ehrich et al.
(2004), from their structured analysis of over 300
research-based papers on mentoring across three
discipline (educational settings, medical and business
context). The results from a one-year longitudinal
quasi-experiment by Seibert (1999), which examined
the effectiveness of a formal mentoring program at a
Fortune 100 corporation, also reported significantly
higher levels of job satisfaction. Though the mentees’
and mentors’ perception about the mentoring program
was not evaluated in this study, one may assume
that the mentees derived immense benefit from the
mentoring program. This could be inferred from their
request for training in other areas that were not
covered during the documentation review. This
perceived acceptance of mentoring as GMP training
tool answers positively the Research question 4:
Can mentoring gain acceptance as GMP training
method in the pharmaceutical manufacturing industry
in Nigeria?
The creation of GAT and sample SOP of SOPs and
other sample SOPs used for the mentoring sessions
is a creative way of using mentoring for GMP training.
This certainly will aid understanding and application of
the knowledge gained from the process. Also,
explanation of the rationale behind the requirements
in the guidelines using examples that the mentees
could relate with is another way of aiding
understanding and will motivate them to implement
what was learnt. This study shows that use of
mentoring as a GMP training method answered
positively Research question 3: “Can mentoring
serve as a method for presenting GMP training to aid
knowledge transfer and ease of understanding and
application of knowledge acquired?” The creation and
use of GAT, the sample SOP of SOPs and other
sample SOPs for the mentoring sessions in this study
is a creative way of applying mentoring to GMP
training. This approach enhanced understanding and
will certainly aid mentees to apply the knowledge
gained to their job. Also, explanation of the rationale
behind the requirements in the guidelines using
examples that the mentees could relate with is
another way of aiding understanding and will motivate
them to implement what was learnt. Therefore, the
use of mentoring for GMP training in this study
answered positively Research question 3, which is
“Can mentoring serve as a method for presenting
GMP training to aid knowledge transfer and ease of
understanding and application of knowledge
acquired?”
The use of sample SOP of SOPs and the other
sample SOPs, as well as the completed GAT for the
training, shows that mentoring is practical and specific
to the organizational needs as opposed to the
classroom method of training, which uses generic,
high level training materials. This study demonstrated
that use of mentoring as a GMP training method has
potential to aid understanding and applicability of
knowledge acquired. This is in alignment with the
result of capacity building for scientific and
professional development of researchers in low- and
middle-income countries (LMICs) reported by Pillai et
al (2018) in which mentorship was a component of the
program. Evaluation of the program showed strong
evidence of knowledge and skills transfer and
personal report by the researchers (mentees)
confirmed that the program had impact on their
research output and their personal career. The
program demonstrated an example of how multi-
sectoral partners can contribute to scientific and
professional development of researchers in LMICs.
It also supports the idea that capacity-building efforts
should be tailored to the specific needs of
beneficiaries to be maximally effective. Lessons
learned from the program may be applied to the
design and conduct of other programs to strengthen
science ecosystems in LMICs. (Pillai et al, 2018).
In this study, sharing of past experiences by the
mentors provided psychological support to the
mentees, letting them know that the mentors have
been through what they were going through and with
their knowledge and experience, capable of
supporting them (the mentees) to achieve their
developmental goals. This supports the report of one
of the benefits mentees acknowledged in the study by
Harris et al., (2015).
Therefore, this study has proved that the
improvement in GMP that could not be achieved in the
pharmaceutical manufacturing industry in Nigeria for
decades through classroom training is possible within
a short period of time through use of mentoring.
However, proper planning and implementation by
competent and empathic mentors as well as
participation by highly motivated mentees are
essential for the success of the program.
Though this study has shown some potential in the
use of mentoring as a GMP capability building tool,
there are some limitations that may not allow
generalization of the results. The use of convenience
sampling in selection of XYZ pharmaceutical
manufacturing company for conduct of this study was
a limitation. This sampling method was used because
it was easier to negotiate access to the organization
through existing contact. This was in alignment with




         
        
         
         
     
           
        
         
          
           
         
    
      
        
        
          
          
             
       
  
           
       
      
       
          
       
      
         
     
        
        
         
      
        
         
       
           
       
         
            
        
        
        
      
   
     
        
    
      
       
         
       
     
       
  
       
    
     
     
      
     
    
       
    
    
      
   
        
       
        
    
      
       
       
       
        
  
         
        
        




Another limitation is that the review of the GMP
documentations of XYZ pharmaceutical was based
on the subjective judgment of the researcher and the
SMEs. Their judgement was influenced by their
o SOP of SOPs designed according to
the regulatory requirements is the
guide to proper design of all other
SOPs.
academic and professional background, experiences
and culture. Therefore, it may not be easy for other
researchers to replicate the study and get similar
o Effective SOPs are the foundation for
building sound GMP processes.
outcomes. On the other hand, the background of the
researcher and the SMEs was a positive for this study.
In addition to the other limitations is that the study was
conducted in only one company. Also, only the GMP
documentations of XYZ pharmaceutical
manufacturing company presented to the researcher
o Preparation of SOPs requires
collaboration between the SMEs and
users of the SOPs to ensure
compliance and ease of applicability
of SOPs by users.
were reviewed. GMP records, and other existing GMP • The above lessons will enable the
documents not presented, were not covered in this
study. It could be pointed out that SOPs are the
foundation for good GMP. Therefore, this is a logical
place to begin a study like this one. The first step is
to write a compliant SOP for SOPs.
•
management of XYZ pharmaceutical
manufacturing company make short-,
medium- and long-term development plans for
their QMS.
It is recommended that additional research be
4. CONCLUSION
conducted on use of formal group mentoring
as a GMP capability building tool in the
The finding that most of the SOPs were deficient as a
result of poor design (which originated from non-
compliant Standard Operating Procedure on Writing
of Standard Operating Procedures [SOP of SOPs])
was a major outcome of the study. Good SOPs are
fundamental to the GMP process. Establishment of
effective SOPs requires collaboration between the
pharmaceutical manufacturing industry in
Nigeria. Additional research will facilitate
understanding of specific factors that will affect
mentoring as a GMP capability building tool,
thereby providing data for planning for future
studies and for development of the industry in
general.
Subject Matter Experts and those who will use the
SOPs to perform their work.
• It is also recommended that lessons learned in
this and future studies be applied to improve
This study revealed that mentoring (formal group
mentoring) is a promising tool for GMP capability
mentoring as a GMP capability building tool in
the Sub-Saharan African region.
building, making it likely to yield faster development of
the GMP standards in the pharmaceutical
manufacturing industry in Nigeria. This is the first
study on use of mentoring as GMP capability building
tool in the pharmaceutical manufacturing industry in
Nigeria as no study on this topic was found in the
literature search performed. The outcome of this
study forms a foundation on which further studies on
this topic can be built so that in the near future, this
approach to GMP capability building will be better
understood and structured. Achievement of this goal
will yield the long-awaited development of the Quality
Systems of pharmaceutical manufacturing industry in
Nigeria.
5. RECOMMENDATIONS FOR NEXT STEPS
• It is recommended that the management of
XYZ pharmaceutical manufacturing company
(the organization where this project was
conducted) apply the lessons from this study
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